

1 Immunity to non-dengue flaviviruses impacts dengue virus IgG ELISA specificity in Cambodia

2

3 Camila Odio¹, Christina Yek^{2, 3*}, Chloe M. Hasund^{1*}, Somnang Man², Piseth Ly², Sreynik

4 Nhek², Sophana Chea², Chanthap Lon², Charlie Voirin¹, Rekol Huy⁴, Rithea Leang⁴, Chea

5 Huch⁴, L. Fabiano Oliveira^{2, 3}, Jessica E. Manning^{2, 3, +}, Leah C. Katzelnick^{1, +}

6

7 **Affiliations:** ¹Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases,

8 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,

9 MD 20892, USA, ²International Center of Excellence in Research, National Institute of Allergy

10 and Infectious Diseases, National Institutes of Health, Phnom Penh, Cambodia, ³Laboratory of

11 Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National

12 Institutes of Health, Bethesda, MD 20892, ⁴National Center for Parasitology, Entomology, and

13 Malaria Control, Ministry of Health, Phnom Penh, Cambodia.

14

15 *Authors made equal contributions to this manuscript.

16

17 **⁺Corresponding authors:**

18

19 Leah Katzelnick PhD MPH

20 Chief, Viral Epidemiology and Immunity Unit

21 National Institutes of Allergy and Infectious Diseases, National Institutes of Health

22 Building 33, Room 3W10A, 33 North Drive

23 Bethesda, MD 20892-3203

24 Phone: 240-627-3276, Email: leah.katzelnick@nih.gov

25

26 Jessica Manning MD MSc

27 Director, International Center of Excellence in Research CAMBODIA

28 National Institutes of Allergy and Infectious Diseases, National Institutes of Health

29 Email: jess.manning@gmail.com

30

31

32 **Abstract 92 words**

33 Seroprevalence studies are the gold standard for disease surveillance, and serology was used to
34 determine eligibility for the first licensed dengue vaccine. However, expanding flavivirus
35 endemicity, co-circulation, and vaccination complicate serology results. Among 713 healthy
36 Cambodian children, a commonly used indirect dengue virus IgG ELISA (PanBio) had a lower
37 specificity than previously reported (94% vs. 100%). Of those with false positive PanBio results,
38 46% had detectable neutralizing antibodies against other flaviviruses, with the highest frequency
39 against West Nile virus (WNV). Immunity to non-dengue flaviviruses can impact dengue
40 surveillance and potentially pre-vaccine screening efforts.

41

42 **Manuscript: 1,696 words**

43 **Background**

44 The genus *Orthoflavivirus* includes multiple pathogenic mosquito-borne viruses including
45 dengue viruses 1-4 (DENV1-4), Japanese encephalitis virus (JEV), West Nile virus (WNV), Zika
46 virus (ZIKV) and yellow fever virus (YFV) [1]. With expanding vector habitats, known
47 flaviviruses are rising in global incidence, and novel flaviviruses are emerging [2, 3]. These
48 flaviviruses commonly co-circulate, and the antibodies induced by one exposure may cross-react
49 with others in the genus [4]. Additionally, affected areas use vaccines to protect against JEV and
50 YFV, further complicating serology. As flaviviruses expand their range and vaccination
51 increases, differentiating true exposure from cross-reactivity is not only difficult, but also
52 increasingly important to guide diagnostic, preventative, and therapeutic measures.

53

54 Accurately characterizing population level immunity to DENV is important for current dengue
55 vaccination efforts. Dengvaxia (Sanofi Pasteur), the first widely approved dengue vaccine, was
56 originally recommended in 2016 by the World Health Organization (WHO) Strategic Advisory
57 Group of Experts (SAGE) panel for use in areas with $\geq 70\%$ DENV seroprevalence in children
58 age 9 and older, with seroprevalence most often measured using common IgG ELISAs [5]. When
59 it was later shown that Dengvaxia increases the risk of severe disease in DENV-naïve
60 individuals, the WHO recommended use of highly specific individual-level testing of DENV
61 immunity to confirm vaccine eligibility, as well as use in high-risk populations in endemic areas
62 [6][7]. The World Health Organization has since recommended that the second licensed dengue
63 vaccine QDenga (Takeda) be introduced to children aged 6 to 16 years, also in highly endemic
64 areas [8]. Given the lack of observed vaccine-induced protection against DENV3 in seronegative
65 individuals and the unknown protection against DENV4 [9], a strategy based on population-level
66 estimates of endemicity has the potential to increase disease risk for seronegative individuals.

67
68 Population-level serosurveys for DENV conducted for surveillance purposes generally use
69 commercial IgG ELISAs. The plaque reduction neutralization test (PRNT), which measures
70 neutralizing antibodies (nAbs) to DENV, is considered the gold standard for evaluating
71 specificity but requires intensive and specialized labor. The PanBio indirect DENV IgG ELISA
72 (Abbott, Brisbane, QLD, Australia) is one of the most commonly used assays for measuring
73 DENV immunity, and the manufacturer reports 100% specificity based on 108 DENV-naïve
74 individuals from endemic areas [10]. Separate work demonstrated 99% specificity of this ELISA
75 using DENV1-4 PRNT₅₀ ≥ 10 as the standard for DENV immunity in a cohort of 534 individuals
76 from both the USA and dengue-endemic regions before 2016 [11]. However, the PanBio indirect

77 DENV IgG ELISA yields higher false positivity rates when evaluated with individuals positive
78 to other flaviviruses, including those who had received an inactivated JEV vaccine (3%), or had
79 immunity against ZIKV (34%) or WNV (51%) [11]. The degree to which immunity to other
80 flaviviruses affects DENV serosurveys is dependent on the site, and a major challenge is that the
81 extent of circulation of other flaviviruses is often unknown. For instance, an observational study
82 of children aged 9-14 years in the Philippines in 2017 used a PRNT₇₀≥40 as the indicator of
83 DENV immunity and reported a relatively low ELISA specificity, of 93.4%. Of the false positive
84 samples, 64% had nAb against ZIKV or JEV, in a region where ZIKV was not thought to be
85 widespread. Thus, although the PanBio ELISA has a reportedly high specificity, this number
86 may vary with flavivirus cross-reactivity and expanding co-circulation or vaccination.

87

88 Here, we examine the performance of the PanBio ELISA in young children in Cambodia, a
89 highly dengue-endemic area. ZIKV was recently found to co-circulate in the area, and JEV is
90 endemic. JEV vaccination campaigns with a live-attenuated JEV vaccine SA14-14-2 started
91 around 2014, and WNV nAb have been identified in birds but not humans [12-15].

92

93

94 **Methods**

95 The study protocol was approved by the institutional review boards at the US National Institutes
96 of Health and the National Ethics Committee on Human Research in Cambodia. The guardians
97 of all pediatric participants provided signed informed consent to participate in the study.

98 Between July and August of 2018, 771 children aged 2-9 years living in Kampong Speu,

99 Cambodia were enrolled in a prospective longitudinal cohort (NCT03534245) [16]. At entry, the

100 PanBio indirect DENV IgG ELISA was performed on sera from 770 individuals. For the 273
101 participants with ELISA values >1.1 (defined as DENV positive by the manufacturer), PRNTs
102 were performed using clinical isolates of DENV1-4 [17]. All PRNTs were performed on Vero
103 cells, as described previously, starting at a serum dilution of 1:5 followed by the addition of an
104 equal volume of virus. Thus, the lower limit of detection was a dilution of 1:10 [18]. The nAb
105 titer was defined as the reciprocal of the calculated dilution wherein virus infectivity was reduced
106 by 50% (PRNT₅₀). PRNT₅₀ \geq 1:10 (reported as PRNT₅₀ \geq 10) against any DENV serotype was
107 considered immune to that serotype. To assess for non-dengue flavivirus nAbs, PRNTs were
108 performed using the following strains: ZIKV-PARAIBA/2015, a chimeric vaccine candidate,
109 WNV/DEN4 Δ 30 [19], and JEV vaccine strain SA14-14-2 (Figure 1A-B). Consistent with prior
110 classifications, seropositivity to any non-dengue flavivirus was defined as PRNT₅₀ \geq 10 [20-22].
111 Statistical comparisons were done in RStudio for macOS (2022.07.1, Build 554) using tidyverse
112 and gtsummary packages. Heatmaps were generated in PRISM (v.9 for macOS).

113

114 **Results**

115 Of the 770 individuals, n=440 had ELISA $<$ 0.2 and were considered DENV naïve per work
116 confirming a strong correlation between ELISA $<$ 0.2 and negative PRNT [23]. Fifty-seven
117 individuals were excluded: 44 had ELISA values between 0.2-0.9 without a confirmatory PRNT
118 and 13 had ELISA values between 0.9-1.1, which the manufacturer considers equivocal
119 immunity. Of the 273 individuals with ELISA $>$ 1.1, n=28 were DENV negative by PRNT (‘false
120 positive’), n=245 were DENV positive (‘immune’), and there were no false negatives, resulting
121 in a 100% sensitivity and 94% specificity of the ELISA assay. Comparison of the naïve, false
122 positive, and immune groups revealed that both the mean age and ELISA value of the false

123 positive group fell between those of the naïve and immune groups ($p < 0.001$, Table 1A). Over the
124 two years of surveillance, there were few PCR-confirmed cases of symptomatic dengue ($n=46$)
125 with no differences in frequency among groups ($p=0.7$).

126

127 We hypothesized that the discordance between the DENV ELISA IgG and PRNT results could
128 be due to cross-reactivity against non-dengue flaviviruses. To test this, we compared the
129 frequencies of nAbs against JEV, ZIKV, and WNV in the false positive individuals versus $n=50$
130 randomly chosen naïve individuals (Figure 1A-B). Consistent with prior classifications,
131 seropositivity was defined as $\text{PRNT}_{50} \geq 10$ [20-22]. Overall, 46% of the false positive group had
132 $\text{PRNT}_{50} \geq 10$ against ≥ 1 other flavivirus versus 20% of the naïve group ($p=0.020$, Table 1B).

133 Although the false positive group had higher percentages of individuals with positive JEV and
134 ZIKV nAbs, only WNV nAbs were significantly more common than in the naïve group (0% vs.
135 25%, $p < 0.001$). To further assess these trends, we tested $n=21$ individuals with DENV
136 $\text{ELISA} > 1.1$ and DENV PRNT between 10-20 (Figure 1). This group has low DENV nAbs and
137 has been considered DENV negative in other work [16, 23]. When compared to the false positive
138 group, the low DENV nAb group had similar frequencies of JEV, ZIKV, and WNV nAb ($p \geq 0.4$
139 for all three nAbs, Table 1B). Thus, immunity to other flaviviruses may contribute to high
140 ELISA values in individuals with undetectable and low DENV nAbs.

141

142 To help identify the primary exposure in the 13 individuals with $\text{PRNT}_{50} \geq 10$ against ≥ 2
143 flaviviruses, PRNT_{90} titers were calculated [4]. Of these, $n=4$ had $\text{PRNT}_{90} < 10$ against all 4
144 flaviviruses, and $n=3$ had $\text{PRNT}_{90} \geq 10$ to multiple flaviviruses: $n=2$ to JEV and WNV, $n=1$ to
145 JEV, WNV, and ZIKV (Figure 1C-D). Six individuals had $\text{PRNT}_{90} \geq 10$ against only 1 flavivirus:

146 n=1 to ZIKV, n=3 to JEV, and n=2 to WNV. Of the two individuals with PRNT₉₀≥10 against
147 WNV only, one had received a JEV vaccine and had a PRNT₅₀≥10 against JEV and one had
148 PRNT₅₀≥10 against ZIKV. While the PRNT₉₀≥10 against WNV only suggests a primary WNV
149 infection, it is possible that JEV vaccination and ZIKV primary exposure induced highly cross-
150 reactive WNV nAb [24]. There were also two individuals with low DENV nAb and PRNT₅₀≥10
151 against WNV only. Although these individuals did not have PRNT₉₀≥10 against DENV or
152 WNV, one had WNV titer that was 2-fold higher than DENV titer. Again, this finding is
153 suggestive of primary WNV infection, but cross-reactivity after DENV exposure cannot be ruled
154 out. Regardless of the WNV nAb source, this immunity was common and likely central to the
155 decreased ELISA specificity observed.

156

157 **Discussion**

158 We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in
159 prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb
160 with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV
161 cross-reactivity [25], and it is possible that the WNV nAb were induced by JEV vaccination or
162 infection. Alternatively, the WNV nAbs may represent true WNV exposure, underlining the need
163 for ongoing vigilance for WNV circulation in humans in Cambodia. Additionally, half of the
164 false positive results remained unexplained, potentially due to waning immunity or infection by
165 unidentified flaviviruses.

166

167 Clinicians, investigators, and public health authorities should be aware that expanding flavivirus
168 co-circulation and vaccination could increasingly impact serology results. Serosurveys conducted

169 for vaccination campaigns to identify populations where dengue is endemic may overestimate
170 dengue burden as a result of false positivity due to infection or vaccination with other
171 flaviviruses. Such population-based strategies are of particular concern when identifying target
172 populations for dengue vaccines where safety in DENV seronegative individuals has not yet
173 been confirmed. Adverse events in these individuals could greatly impact vaccine trust and
174 uptake, as occurred with Dengvaxia [26]. For vaccines that are known to be unsafe in
175 seronegative individuals like Dengvaxia, pre-vaccination screening is required to determine
176 vaccine eligibility, which allows individuals to make informed decisions about their own vaccine
177 risk and benefit. It is recommended that past infection be confirmed either by virological assay
178 or by two specific serological assays, such as the anti-DENV1-4 NS1 ELISA IgG and a IgG
179 rapid test [7]. Evaluation of false positivity due to infection with other emerging flaviviruses is
180 critical to ensuring the safety of this screening approach.

181


182 Overall, our study demonstrates that the PanBio IgG ELISA and even PRNT results should be
183 interpreted with caution in areas with flavivirus co-circulation and vaccines, and multiple tests
184 may be required to confirm DENV seroprevalence.

185

186

187

188



189
 190 **Figure 1.** Neutralizing antibody titers against DENV, JEV, WNV, ZIKV in individuals who
 191 were false positive (ELISA>1.1, DENV PRNT₅₀<10), naïve (ELISA<0.2), or had low DENV
 192 nAb (ELISA>1.1, DENV PRNT₅₀ of 10-20) as measured by PRNT₅₀ (A-B) and PRNT₉₀ titers
 193 (C-D). PRNT₉₀ titers were only measured in those with nAb against ≥ 2 non-dengue flaviviruses.

194
 195
 196
 197
 198
 199
 200

201 **Table 1.** Characteristics and immune profiles of individuals who were naïve (ELISA<0.2), false
 202 positive (ELISA>1.1, PRNT₅₀<10), or DENV immune (ELISA>1.1, PRNT₅₀≥10). The presence
 203 of neutralizing antibodies against non-dengue flaviviruses were compared in the naïve and false
 204 positive groups and between the false positive and the low DENV immune group (ELISA>1.1,
 205 PRNT₅₀ 10-20).

206 A. Cohort characteristics

Characteristics	Naïve (n=440)*	False positive (n=28)	Immune (n=245)	p-value [†]
Age	4.9 (2.0)	6.0 (2.2)	6.8 (2.2)	<0.001
Sex				0.2
Female	230 (52)	10 (36)	126 (51)	
Male	210 (48)	18 (64)	119 (49)	
ELISA IgG value	0.03 (0.04)	2.00 (0.72)	2.92 (0.84)	<0.001
Dengue case				0.7
No dengue	321 (91)	22 (92)	156 (93)	
Symptomatic dengue	32 (9)	2 (8)	12 (7)	
Unknown [‡]	87	4	77	

207

208 B. Immunity subset analysis

Immunity profile	Naïve (n=50)	p-value [§]	False positive (n=28)	p-value [¶]	Low DENV nAb (n=21)
JEV nAb		0.058		0.4	

Negative	41 (82)		17 (61)		16 (76)
Positive	9 (18)		11 (39)		5 (24)
ZIKV nAb		0.3		0.4	
Negative	48 (96)		25 (89)		17 (81)
Positive	2 (4)		3 (11)		4 (19)
WNV nAb		<0.001		0.5	
Negative	50 (100)		21 (75)		14 (67)
Positive	0 (0)		7 (25)		7 (33)
≥1 Flavivirus positive	10 (20)	0.020	13 (46)	>0.9	10 (48)
≥2 Flavivirus positive	1 (2)	0.003	7 (25)	>0.9	5 (24)

209

210 *Mean (SD) or no. (%)

211 †One-way ANOVA, Pearson's Chi-squared test; Fisher's exact test

212 ‡Unknown indicates that participant was lost to follow-up prior to final study visit at 24 months

213 §Fisher's exact test comparing naïve vs. false positive group.

214 ¶Fisher's exact test comparing false positive group vs. low DENV nAb group.

215 Dengue virus, DENV; Japanese encephalitis virus, JEV; neutralizing antibodies, nAb; West Nile

216 virus, WNV; Zika virus, ZIKV

217

218

219 **Acknowledgements:** The authors would like to thank Patrick Mpingabo for his support
220 establishing ELISA assays to evaluate samples for antibodies against the nonstructural-1 proteins
221 of JEV, ZIKV, and WNV. These assays were not ultimately used in the manuscript. We would
222 also like to thank Kelsey Lowman for her support completing the WNV and JEV PRNT assays.

223

224 **Funding:** This research was supported by the Intramural Research Program at the National
225 Institute of Allergy and Infectious Diseases.

226

227 **Conflict of Interest:** The authors declare no conflict of interest.

228

229 This work was presented as a poster at the American Society of Tropical Medicine and Hygiene
230 annual conference in October 2023.

231

232 **References**

233 1. Postler TS, Beer M, Blitvich BJ, et al. Renaming of the genus *Flavivirus* to *Orthoflavivirus*
234 and extension of binomial species names within the family *Flaviviridae*. *Archives of Virology*
235 **2023**; 168:224.

236 2. Du M, Jing W, Liu M, Liu J. The Global Trends and Regional Differences in Incidence of
237 Dengue Infection from 1990 to 2019: An Analysis from the Global Burden of Disease Study
238 2019. *Infectious Diseases and Therapy* **2021**; 10:1625-43.

239 3. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. *Nature*
240 *Microbiology* **2020**; 5:796-812.

- 241 4. Chan KR, Ismail AA, Thergarajan G, et al. Serological cross-reactivity among common
242 flaviviruses. *Front Cell Infect Microbiol* **2022**; 12:975398.
- 243 5. Secretariat SWGoDVaWHO. Background paper on dengue vaccines. Available at:
244 [https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Apr2016/10_session_dengue/A](https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Apr2016/10_session_dengue/Apr2016_session10_dengue_vaccines.pdf)
245 [pr2016_session10_dengue_vaccines.pdf](https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Apr2016/10_session_dengue/Apr2016_session10_dengue_vaccines.pdf). Accessed 11/17/2023.
- 246 6. WHO. Dengue vaccine: WHO position paper. *Weekly epidemiological record* **2018**; 93:457-
247 76.
- 248 7. Prevention CfDca. Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue
249 Vaccine. Available at: <https://www.cdc.gov/dengue/vaccine/hcp/testing.html>. Accessed October
250 31 2023.
- 251 8. Takeda. Takeda's Dengue Vaccine Recommended by World Health Organization Advisory
252 Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to
253 16 Years. Available at: [https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-](https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years/)
254 [Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-](https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years/)
255 [High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years/](https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years/). Accessed
256 October 31 2023.
- 257 9. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda's Dengue
258 Vaccine Candidate (TAK-003). *Clinical Infectious Diseases* **2021**.
- 259 10. Abbott. Panbio™ DENGUE IgG CAPTURE ELISA. Available at:
260 [https://www.globalpointofcare.abbott/au/en/product-details/panbio-dengue-igg-capture-](https://www.globalpointofcare.abbott/au/en/product-details/panbio-dengue-igg-capture-elisa.html)
261 [elisa.html](https://www.globalpointofcare.abbott/au/en/product-details/panbio-dengue-igg-capture-elisa.html). Accessed August 29 2023.

- 262 11. Bonaparte M, Zheng L, Garg S, et al. Evaluation of rapid diagnostic tests and conventional
263 enzyme-linked immunosorbent assays to determine prior dengue infection. *J Travel Med* **2019**;
264 26.
- 265 12. Yek C, Li Y, Pacheco AR, et al. National dengue surveillance, Cambodia 2002-2020. *Bull*
266 *World Health Organ* **2023**; 101:605-16.
- 267 13. Duong V, Ong S, Leang R, et al. Low Circulation of Zika Virus, Cambodia, 2007-2016.
268 *Emerg Infect Dis* **2017**; 23:296-9.
- 269 14. Horwood PF, Duong V, Laurent D, et al. Aetiology of acute meningoencephalitis in
270 Cambodian children, 2010-2013. *Emerg Microbes Infect* **2017**; 6:e35.
- 271 15. Auerswald H, Ruget AS, Ladreyt H, et al. Serological Evidence for Japanese Encephalitis
272 and West Nile Virus Infections in Domestic Birds in Cambodia. *Front Vet Sci* **2020**; 7:15.
- 273 16. Manning JE, Chea S, Parker DM, et al. Development of Inapparent Dengue Associated With
274 Increased Antibody Levels to *Aedes aegypti* Salivary Proteins: A Longitudinal Dengue Cohort in
275 Cambodia. *The Journal of Infectious Diseases* **2021**.
- 276 17. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live
277 dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
278 *Am J Trop Med Hyg* **2001**; 65:405-13.
- 279 18. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and
280 validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to
281 four serotypes of dengue virus used in support of dengue vaccine development. *Am J Trop Med*
282 *Hyg* **2013**; 88:962-70.

- 283 19. Pierce KK, Whitehead SS, Kirkpatrick BD, et al. A Live Attenuated Chimeric West Nile
284 Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older
285 Adult Volunteers. *The Journal of Infectious Diseases* **2016**; 215:52-5.
- 286 20. Plotkin SA. Correlates of protection induced by vaccination. *Clin Vaccine Immunol* **2010**;
287 17:1055-65.
- 288 21. Sornjai W, Jaratsittisin J, Auewarakul P, Wikan N, Smith DR. Analysis of Zika virus
289 neutralizing antibodies in normal healthy Thais. *Sci Rep* **2018**; 8:17193.
- 290 22. Kaiser JA, Barrett ADT. Twenty Years of Progress Toward West Nile Virus Vaccine
291 Development. *Viruses* **2019**; 11.
- 292 23. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
293 ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
294 prospective population-based study. *The Lancet Global Health* **2021**; 9:e44-e51.
- 295 24. Hou B, Chen H, Gao N, An J. Cross-Reactive Immunity among Five Medically Important
296 Mosquito-Borne Flaviviruses Related to Human Diseases. *Viruses* **2022**; 14:1213.
- 297 25. Mansfield KL, Horton DL, Johnson N, et al. Flavivirus-induced antibody cross-reactivity. *J*
298 *Gen Virol* **2011**; 92:2821-9.
- 299 26. Larson HJ, Hartigan-Go K, de Figueiredo A. Vaccine confidence plummets in the
300 Philippines following dengue vaccine scare: why it matters to pandemic preparedness. *Hum*
301 *Vaccin Immunother* **2019**; 15:625-7.
- 302